IP Library › Assignment 023649/0752
Patent Assignment
Reel/Frame 023649/0752

Assignment of Assignor's Interest

Recorded: 2009-12-15 Pages: 8
Assignor
PDL BIOPHARMA, INC.
Executed: 2009-03-09
Assignee
FACET BIOTECH CORPORATION
1500 SEAPORT BLVD., REDWOOD CITY, CALIFORNIA, 94063
Covered Properties (29)
Bispecific Antibody Heterodimers
Patent: 5,932,448 →
Application: 07/801,798 →
Constructs Encoding Recombinant Antibody-Toxin Fusion Proteins
Patent: 6,051,405 →
Application: 07/865,722 →
Cross-Reacting Monoclonal Antibodies Specific for E- and P-Selectin
Patent: 5,622,701 →
Application: 08/259,963 →
Increasing Antibody Affinity by Altering Glycosylation in the Immunoglobulin Variable Region
Patent: 5,714,350 →
Application: 08/372,262 →
Bispecific Antibody Effective to Treat B-Cell Lymphoma and Cell Line
Patent: 6,129,914 →
Application: 08/397,411 →
Recombinant Antibody-Toxin Fusion Protein
Patent: 5,863,745 →
Application: 08/461,825 →
Recombinant Antibody-Toxin Fusion Protein
Patent: 5,696,237 →
Application: 08/463,163 →
Humanized Antibodies Reactive with L-Selectin
Patent: 6,210,671 →
Application: 08/579,378 →
Cross-Reacting Monoclonal Antibodies Specific for E-Selectin and P-Selectin
Patent: 6,210,670 →
Application: 08/619,491 →
Monoclonal Antibodies Specific for the Platelet Derived Growth Factor Beta Receptor and Methods of Use Thereof
Patent: 5,882,644 →
Application: 08/621,751 →
Mutated Nonactivating IGG2 Domains and Anti-CD3 Antibodies Incorporating the Same
Patent: 5,834,597 →
Application: 08/656,586 →
Fas Ligand Fusion Proteins and Their Uses
Patent: 6,046,310 →
Application: 08/815,190 →
Antibodies with Increased Binding Affinity
Patent: 6,350,861 →
Application: 08/862,871 →
Method of Preventing Acute Rejection Following Solid Organ Transplantation
Patent: 6,013,256 →
Application: 08/934,841 →
Humanized Antibodies to Gamma-Interferon
Patent: 6,329,511 →
Application: 09/450,520 →
Animal Model for Psoriasis for the Prevention and Treatment of Psoriasis in Humans
Patent: 6,410,824 →
Application: 09/457,912 →
Novel Methods of Diagnosing Cancer, Compositions, and Methods of Screening for Cancer Modulators
Patent: 6,566,502 →
Application: 09/608,821 →
Humanized Antibodies Against CD3
Patent: 7,381,803 →
Application: 09/618,380 →
Novel Methods for Detection and Diagnosing of Breast Cancer
Patent: 6,750,013 →
Application: 09/747,371 →
Publication: US 2002/0006616
Novel Methods of Diagnosing Colorectal Cancer, Compositions, and Methods of Screening for Colorectal Cancer Modulators
Patent: 6,682,890 →
Application: 09/851,588 →
Publication: US 2002/0042067
Humanized Antibodies to Gamma-Interferon
Patent: 7,183,390 →
Application: 09/992,524 →
Publication: US 2002/0091240
Increasing Antibody Affinity by Altering Glycosylation of Immunoglobulin Variable Region
Patent: 6,933,368 →
Application: 10/084,825 →
Publication: US 2003/0054497
Methods of Diagnosis of Ovarian Cancer, Compositions and Methods of Screening for Modulators of Ovarian Cancer
Patent: 7,189,507 →
Application: 10/173,999 →
Publication: US 2004/0005563
Anti-Hla-Dr Antibodies and the Methods of Using Thereof
Patent: 6,894,149 →
Application: 10/268,883 →
Publication: US 2003/0138862
Amphiregulin Antibodies and Their Use to Treat Cancer and Psoriasis
Patent: 7,223,393 →
Application: 10/774,076 →
Publication: US 2004/0210040
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,361,740 →
Application: 10/822,300 →
Publication: US 2005/0014934
Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer
Patent: 7,399,469 →
Application: 11/089,872 →
Publication: US 2005/0260212
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,365,168 →
Application: 11/102,621 →
Publication: US 2005/0276799
Methods of Diagnosis of Ovarian Cancer, Compositions and Methods of Screening for Modulators of Ovarian Cancer
Patent: 7,435,589 →
Application: 11/625,458 →
Publication: US 2007/0154928
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 28, 1996
From: CHANG, CHUNG NAN; LANDOLFI, NICHOLAS; MARTIN, ULRICH
To: PROTEIN DESIGN LABS, INC.; BOEHRINGER MANNHEIM GMBH
Reel/Frame 008148/0308 →
Assignment of Assignor's Interest Nov 12, 1996
From: ANASETTI, CLAUDIO
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 008217/0886 →
Assignment of Assignor's Interest Nov 12, 1996
From: TSO, J. YUN; COLE, MICHAEL S.
To: PROTEIN DESIGN LABS, INCORPORATED
Reel/Frame 008216/0328 →
Assignment of Assignor's Interest Oct 9, 2001
From: MACK, DAVID; GISH, KURT C.; WILSON, KEITH E.
To: EOS BIOTECHNOLOGY, INC.
Reel/Frame 012246/0289 →
Assignment of Assignor's Interest Sep 25, 2003
From: VASQUEZ, MAXIMILIANO; LANDOLFI, NICHOLAS F.; TSURUSHITA, NAOYA; QUEEN, CARY L.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014562/0232 →
Assignment of Assignor's Interest Nov 3, 2003
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014661/0402 →
Assignment of Assignor's Interest Feb 6, 2004
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014967/0744 →
Assignment of Assignor's Interest Jan 17, 2006
From: ROCHE DIAGNOSTICS GMBH
To: PDL BIOPHARMA, INC.
Reel/Frame 017015/0693 →
Change of Name Feb 17, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017186/0110 →
Merger Apr 11, 2006
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017455/0630 →
Change of Name Apr 13, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017465/0495 →
Change of Name Apr 17, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017480/0264 →
Merger May 1, 2006
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017555/0288 →
Change of Name May 1, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017555/0284 →
Change of Name May 19, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017636/0787 →
Change of Name May 22, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017655/0436 →
Change of Name Sep 26, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 018303/0026 →
Assignment of Assignor's Interest Aug 5, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023056/0251 →
Change of Name Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
Change of Name Dec 9, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025483/0591 →
Change of Name Jul 13, 2011
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP
Reel/Frame 026587/0575 →
Change of Name Feb 18, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029825/0070 →
Change of Name Dec 5, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 031722/0709 →
Change of Name Dec 20, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 031834/0936 →
Change of Name Sep 18, 2014
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC
Reel/Frame 033772/0344 →